With so many scientific reports on animals, Effepharm decided to conduct our own clinical study on Uthever®.
Our clinical study would start from:
(1) Safety assessment
(3) Boosting energy and increasing endurance
The clinical study on Uthever® is registered in the US and WHO’s official clinical registry system and displayed on the websites to the public.
Title: Evaluate the Efficacy and Safety of Uthever NMN(Nicotinamide Mononucleotide, a Form of Vitamin B3)
Official Title: A Multicentre, Randomized, Double-Blind, Parallel Design, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Uthever® (NMN), an Orally Administered Supplementation in Middle-Aged and Older Adults.
US register ID: NCT04228640
Study Type: Interventional (Clinical Trial)
Estimated Enrollment: 66 participants
Intervention Model: Parallel Assignment
Intervention Model Description: A Multicenter, Randomized, Double-Blind, Placebo-Controlled
Primary Purpose: Prevention
To assess its safety, physical examination, blood biochemistry test, BMI, and HOMA will be performed at baseline and end of the study. Blood cellular NAD+ and NADH concentration in serum will de determined to confirm its ability to increase NAD levels in the human body.
Effepharm is proud to be the first and the only NMN Manufacturer in the world to conduct clinical trials. The clinical study on Uthever® is the largest scale in the world according to WHO’s the clinical database.
UTHEVER’s clinical trial report has been published on the frontier in aging. : The rise in the levels of NAD+/NADH at day 30 and day 60 illustrated the potential of Uthever to raise the levels of NAD+ in the cells, which is linked to higher energy levels and an anti-aging effect. Increased sensitivity to insulin has also been linked to antiaging. There was no noteworthy change in HOMA score, in the UTHEVER group whereas there was a noteworthy rise in the placebo group, demonstrating the anti-aging effect of Uthever as in its absence, the parameters worsened. Please check out more details by the below link: